Sumo Logic Announces Upcoming Conference Participation

REDWOOD CITY, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) — Sumo Logic, (Nasdaq: SUMO) the pioneer in continuous intelligence, announced today that members of its management team will present at the following investor conferences: The Morgan Stanley Technology, Media and Telecom Conference, March 2nd at 2:00PM Pacific Time, 5:00 PM Eastern Time The Berenberg Cyber Security & DevOps Conference, […]

FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS)

First international council to support accelerated drug development for Angelman syndrome and related neurodevelopmental disorders DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) — FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a collaboration to launch the International Angelman Syndrome Research Council (INSYNC-AS). Using a robust integrated approach, the Council will evaluate […]

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility GAITHERSBURG, Md., Feb. 18, 2021 […]

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility GAITHERSBURG, Md., Feb. 18, 2021 […]

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility GAITHERSBURG, Md., Feb. 18, 2021 […]

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility GAITHERSBURG, Md., Feb. 18, 2021 […]

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility GAITHERSBURG, Md., Feb. 18, 2021 […]

Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma

–the 3rd sNDA for Toripalimab in China SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) […]

Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma

–the 3rd sNDA for Toripalimab in China SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) […]